Dasatinib hydrochloride

Research use only, not for human use.

A potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively.

A potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively; exhibits two-log increased potency relative to imatinib and retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants; prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-positive bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML.Blood Cancer Approved.

——

Animal Model:Nude mice bearing K562 xenografts Dosage:5 mg/kg and 50 mg/kg Administration:Oral administration on a 5 day on and 2 day off schedule. Result:Showed partial tumor regressions after one treatment cycle and complete disappearance of the tumor mass by the end of drug treatment. No toxicity (animal deaths, lack of weight gain) was observed.Animal Model:Sprague-Dawley Rats Dosage:10 mg/kg (Pharmacokinetic Analysis) Administration:Oral and i.v. Result:Cmax of 13.2 and 0.5 μM for i.v. and oral, respectively.

BMS-354825 hydrochloride | BMS354825 hydrochloride | BMS 354825 hydrochloride

Angiogenesis

Bcr-Abl

Bcr-Abl

Cancer

Blood cancer

854001-07-3

524.4665

C22H27Cl2N7O2S

>98% (HPLC)

DMSO: 15 mg/mL

CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO.Cl

5-Thiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years